Page last updated: 2024-08-26

diosgenin and Non-alcoholic Fatty Liver Disease

diosgenin has been researched along with Non-alcoholic Fatty Liver Disease in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Gao, L; He, S; Jin, R; Lei, M; Li, Z; Peng, X; Shi, C; Wang, X; Yao, Y; Zhong, Y1
Chen, S; Dong, H; Fang, K; Gao, Y; Lu, F; Nie, K; Su, H; Tang, Y; Wang, H; Wang, Z1
Chen, S; Feng, Y; Li, X; Liang, P; Liu, H; Meng, D; Sun, S; Yin, G; Yu, W; Zhang, F; Zhang, X1
Chen, G; Dong, H; Fang, K; Li, J; Lu, F; Wu, F; Xu, L; Zhao, Y; Zou, X1
Cheng, B; Cheng, S; Deng, Z; Du, J; Li, S; Liang, S; Ling, C; Liu, Q; Zhang, Y1
Han, X; Peng, J; Qi, Y; Tao, X; Xu, L; Xu, Y; Yao, H; Yin, L; Zheng, L1

Other Studies

6 other study(ies) available for diosgenin and Non-alcoholic Fatty Liver Disease

ArticleYear
Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats.
    Nutrients, 2022, Nov-24, Volume: 14, Issue:23

    Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Diosgenin; Fatty Acids; Lipogenesis; Liver; Mitochondria; Non-alcoholic Fatty Liver Disease; Rats

2022
Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 111

    Topics: Animals; Diabetes Mellitus, Type 2; Diosgenin; Fatty Acids; Lipid Metabolism; Liver; Mice; Non-alcoholic Fatty Liver Disease; Sirtuins

2023
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARĪ±/CD36 pathway.
    European journal of pharmacology, 2023, Aug-05, Volume: 952

    Topics: Animals; Diosgenin; Fatty Acids; Fatty Acids, Nonesterified; Liver; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1

2023
Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    BMC complementary and alternative medicine, 2019, Sep-13, Volume: 19, Issue:1

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carnitine O-Acetyltransferase; Cell Line; Diosgenin; Fatty Acid Synthases; Humans; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Signal Transduction; Sterol Regulatory Element Binding Protein 1

2019
Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways.
    International journal of molecular medicine, 2018, Volume: 41, Issue:2

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Diosgenin; Hep G2 Cells; Humans; Hydrocarbons, Fluorinated; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Phosphorylation; Rats; Signal Transduction; Sulfonamides; Transcriptional Activation

2018
Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
    Pharmacological research, 2018, Volume: 131

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Diosgenin; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Signal Transduction; Sirtuin 1

2018